Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

IDL Diagnostics secures patent approval in Hong Kong for the use of TK1 protein in respiratory infections

IDL Diagnostics

IDL Diagnosticsl AB (publ) is pleased to announce that its patent application (HK40055647) for the novel use of thymidine kinase 1 (TK1) protein in detecting and categorizing respiratory infections has been granted in Hong Kong. This expands the company’s intellectual property portfolio, following earlier approvals in Europe (EP3966568) and Japan.

The patent covers the use of serum TK1 (sTK1) to predict and diagnose Mycoplasma pneumonia caused by M. pneumoniae, as well as distinguishing it from other bacterial pneumonias based on TK1 protein levels.

The research that supports the patent demonstrates an exciting opportunity to extend the use of our TK1 test to include respiratory infections. By strengthening the protection of our test, we facilitate further commercialization and broader use of our TK1 marker.

Contacts


Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics


IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

Attachments


IDL Diagnostics secures patent approval in Hong Kong for the use of TK1 protein in respiratory infections

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.